Hire an Advanced Robo-Advisor to Trade DGX on Your Behalf.
- Street Sentiment
- Personalized Strategy
- Free Trading Simulator
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
Why Smart Auto-Trading?
Smart Auto-Trading is an advanced robo-advisor designed to provides investors with a trading partner to automate systematic investing. Its robo is designed to screens, monitors and auto-trades elite stocks like QUEST DIAGNOSTICS INCORPORATED (DGX) using artificial intelligence, social media and market data to augments your potential as an investor.
Smart Auto-Trading produces short-term trades which makes it an ideal tool for trading in tax-deferred accounts such as IRA, SIMPLE IRA, Rollover IRA, 529 College Plans, Keoghs and UGMA. It also works in taxable accounts. Just be aware that if you elect to auto-trade using Smart Auto-Trading in a regular brokerage account, you will be taxed at regular income. Make sure you understand your tax situation before using Smart Auto-trading.
Using Smart Auto-Trading is easy. It connects to your brokerage account at Ally Invest, one of the most trusted broker/dealer in the United States. All you need to do is open an account with them, put a minimum of $5,000 in your account and connect Smart Auto-Trading to trade.
There are clear benefits associated with using a robo-advisor such as Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few steps. It auto-trades for you, using your personalized strategy, while you attend more important life events.
Using Smart Auto-Trading is like having thousands of traders working for you to help you reach your financial goals.
Smart Auto-Trading actively trades which is different from passive investing. The robo is on the lookout working to maximize your potential every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.
Robo investing really means that a computer program is tasked to monitor and trade stocks based on your carefully crafted strategy.
Robo investing simplifies stock investing by processing and organizing stocks for the purpose of trading.
Once your strategy is set up, all you need to do is start your simulation. The robo-advisor then executes your strategy by finding and trading stocks that meet specific requirements.
Because you can test and improve your strategy over time, the AI empowers you to find the appropriate strategy without risking your capital.
Time is your ally when it comes down to AI investing. Take your time to refine your simulation and learn about the capabilities of the technology. Patterns will reveal themselves and empower you to develop your real potential.
Smart Auto-Trading is one of the first robo-advisor to take advantage of Government grade listening technology, artificial intelligence, social media and market data natively.
Try Smart Auto-Trading today!
You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.
Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment, investment strategy (including robo-strategies), or product made in reference directly or indirectly on this website, will be profitable or equal to corresponding indicated performance levels. Robot-Advisors like other investment methods rely on favorable market conditions to provide positive outcomes.
QUEST DIAGNOSTICS INCORPORATED (DGX) News
Forsta AP Fonden Sells 21,827 Shares of Quest Diagnostics Incorporated (DGX)
Forsta AP Fonden reduced its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 25.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 63,390 shares of the medical research company’s stock after selling 21,827 shares during the period. Forsta AP Fonden’s holdings in Quest Diagnostics were worth $5,936,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in DGX. WFG Advisors LP increased its stake in Quest Diagnostics by 45.3% during the 2nd quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock worth $107,000 after buying an additional 301 shares during the period. Sun Life Financial INC increased its stake in Quest Diagnostics by 14,142.9% during the 2nd quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock worth $111,000 after buying an additional 990 shares during the period. Parallel Advisors LLC increased its stake in Quest Diagnostics by 0.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock worth $140,000 after buying an additional 12 shares during the period. Acrospire Investment Management LLC increased its stake in Quest Diagnostics by 300.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock worth $178,000 after buying an additional 1,200 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in Quest Diagnostics during the 2nd quarter worth approximately $180,000. 88.52% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on DGX. Bank of America Corporation raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $111.00 to $118.00 in a research note on Tuesday, July 25th. Piper Jaffray Companies upped their target price on shares of Quest Diagnostics to $107.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 25th. BidaskClub downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Finally, ValuEngine raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $106.18.Get Started today! - Risk Free